As a specialty biopharmaceutical company, our aims is to identify, develop and commercialize
important, new, biotherapeutic products that save lives by preventing or treating
serious medical conditions. We are committed to significantly investing in future
R&D portfolio and capabilities in the areas of Oncology, Immunology and allied specialties.
As a Pharma-based company, Rosefinch lifesciences dedicates itself to providing
our scientists with powerful and innovative tools to screen potential new drugs
and identify promising targets for treating medical conditions. In pursuit of drugs
with new mechanisms of action and new delivery systems to treat conditions, our
research seeks to enhance the effectiveness and safety of drug therapy.
Our researchers and clinicians have expertise in Oncology, Immunology, neurology,
pharmacology, pharmaceutics, molecular biology, combinatorial chemistry, In-Silico
Drug Designing and other scientific disciplines.
Rosefinch LifeSciences has developed the target specific biopharmaceuticals addressing
many of the highest priority disease targets in the pharmaceutical industry. Company
has created spectrum of molecules - MRT701, MRT702, MRT703, MRT704, MRT705 which
have shown outstanding preclinical efficacy in in-vitro models of Cancer.
Rosefinch LifeSciences is also focusing on the Multi Drug Resistance (MDR). MDR
Reverter Molecule, – MDP7 has also shown good preclinical study result, which control
and re-establishes the drug efficacy and efflux through ABC transporters in the
target tissue showing inducible chemotherapy resistance. The approach is applicable
to over 20 targets contained in our proprietary database, including several chemokines
and growth factors.
Rosefinch LifeSciences has established and continues to maintain strong long standing
strategic partnerships with academic institutions and other related companies. These
collaborative partnerships support a range of innovative research programs, including
both basic and applied research in therapeutics and recombinant biotechnology.